After nearly a year of treatment, Viltepso (viltolarsen) was well tolerated and tended to increase how fast boys with…
Articles by Margarida Maia, PhD
ITF Therapeutics — which will be responsible for marketing Duvyzat (givinostat), Italfarmaco’s newly approved Duchenne muscular dystrophy (DMD) therapy,…
The U.S. Food and Drug Administration (FDA) has approved Italfarmaco’s givinostat, which will now be marketed as Duvyzat, as…
It may take an average of 11 years before people with Duchenne muscular dystrophy (DMD) lose upper body function…
A committee of the European Medicines Agency (EMA) has maintained its initial recommendation not to renew the conditional marketing authorization…
Corticosteroids may cause fewer unwanted brain changes in boys with Duchenne muscular dystrophy (DMD) if they are given…
The U.S. Food and Drug Administration (FDA) has lifted its clinical hold on PGN-EDODM1, a medicine being developed by…
The European Medicines Agency (EMA) has started reviewing an application to market givinostat for Duchenne muscular dystrophy (DMD).
Pamrevlumab, an antibody in FibroGen’s pipeline, did not improve motor skills in boys with Duchenne muscular dystrophy…
The U.S. Food and Drug Administration (FDA) has granted both orphan drug and rare pediatric disease status to SAT-3153,…